Clinical Trial Update: Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating Zunsemetinib in combination with capecitabine for hormone receptor-positive, HER2-negative metastatic breast cancer with bone metas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastases
• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Zunsemetinib (Zunsemetinib)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer | Phase 1, Phase 2 | Status: RECRUITING